Edition:
United Kingdom

Nice Ltd (NICE.OQ)

NICE.OQ on NASDAQ Stock Exchange Global Select Market

88.83USD
3:59pm GMT
Change (% chg)

$-0.04 (-0.05%)
Prev Close
$88.87
Open
$89.17
Day's High
$89.17
Day's Low
$88.74
Volume
14,517
Avg. Vol
44,755
52-wk High
$89.83
52-wk Low
$65.72

Select another date:

Thu, Nov 2 2017

Israel's Nice tops Q3 estimates, tweaks 2017 profit forecast

JERUSALEM, Nov 2 Israeli software provider Nice narrowed the range of its 2017 earnings estimate after topping third-quarter forecasts boosted by higher revenue in its omni-channel, cloud, analytics and artificial intelligence businesses.

BRIEF-Nice Ltd reports Q3 earnings per share of $0.42

* ‍Q3 2017 total revenues increased 36.1% to $322.8 million compared to $237.2 million for Q3 of 2016​

UK's NICE gives Roche drug green light for bladder cancer

LONDON Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

UK's NICE gives Roche drug green light for bladder cancer

LONDON Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

UK's NICE gives Roche drug green light for bladder cancer

LONDON, Nov 1 Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

BRIEF-Migdal Insurance & Financial Holdings reports 4.95 pct passive stake ​ in Nice as of Oct 26

* Migdal Insurance & Financial Holdings Ltd reports 4.95 percent passive stake ​ in Nice Ltd as of Oct 26 - SEC filing Source text: (http://bit.ly/2lxaLhu) Further company coverage:

UK finds Roche bladder cancer drug too costly for routine use

LONDON Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

UK finds Roche bladder cancer drug too costly for routine use

LONDON Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

UK finds Roche bladder cancer drug too costly for routine use

LONDON, Aug 2 Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

Select another date: